Literature DB >> 11905993

Metabolic changes in the basal ganglia of patients with Huntington's disease: an in situ hybridization study of cytochrome oxidase subunit I mRNA.

Isabelle Gourfinkel-An1, Miquel Vila, Baptiste Faucheux, Charles Duyckaerts, François Viallet, Jean-Jacques Hauw, Alexis Brice, Yves Agid, Etienne C Hirsch.   

Abstract

On the basis of the functional model of the basal ganglia developed in the 1980s and the neuropathological findings in Huntington's disease (HD), changes in the neuronal activity of the basal ganglia have previously been proposed to explain the abnormal movements observed in this pathology. In particular, it has been stated that the neurodegenerative process affecting the basal ganglia in the disease should provoke a hypoactivity in the internal segment of the pallidum (GPi) that could explain choreic movements observed in the disease. To test this functional hypothesis, we performed an in situ hybridization study on control and HD brains postmortem, taking cytochrome oxidase subunit I (COI) mRNAs expression as index of neuronal activity. As most of the HD patients studied were under chronic neuroleptic (NL) treatment, we also studied the brains of non-HD patients under chronic NL treatment. Our results show that in HD brain the number of neurons expressing COI mRNA tends to be lower in the striatum, GPe and GPi, suggesting a severe involvement of these structures during the neurodegenerative process. Moreover, COI mRNA level of expression was markedly reduced within neurons of the putamen and GPe. Surprisingly, COI mRNA expression was not modified in the GPi in HD brains compared with controls. This paradoxical result in the GPi may be explained by the antagonistic effect of GPe hypoactivity and the degenerative process involving neurons of GPi. Our results indicate that the functional modifications, and consequently the pathophysiology of abnormal movements, observed in HD basal ganglia are more complex than expected from the currently accepted model of the basal ganglia organization.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11905993     DOI: 10.1046/j.0022-3042.2001.00734.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  3 in total

1.  αB-Crystallin overexpression in astrocytes modulates the phenotype of the BACHD mouse model of Huntington's disease.

Authors:  Ana Osório Oliveira; Alexander Osmand; Tiago Fleming Outeiro; Paul Joseph Muchowski; Steven Finkbeiner
Journal:  Hum Mol Genet       Date:  2016-02-26       Impact factor: 6.150

Review 2.  Mitochondrial functional alterations in relation to pathophysiology of Huntington's disease.

Authors:  Mritunjay Pandey; Kochupurackal P Mohanakumar; Rajamma Usha
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

3.  Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin.

Authors:  Alexandra Benchoua; Yaël Trioulier; Diana Zala; Marie-Claude Gaillard; Nathalie Lefort; Noelle Dufour; Frederic Saudou; Jean-Marc Elalouf; Etienne Hirsch; Philippe Hantraye; Nicole Déglon; Emmanuel Brouillet
Journal:  Mol Biol Cell       Date:  2006-02-01       Impact factor: 4.138

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.